John Murphy, CEO The COVID-19 Long haul Foundation<\/p>\n\n\n\n
Background:<\/strong> Long COVID is a heterogeneous post-infectious condition associated with persistent neurological, autonomic, cognitive, and sleep-related symptoms. Restless legs syndrome (RLS), a sensorimotor neurological disorder characterized by an urge to move the limbs that worsens during rest and improves with movement, may contribute substantially to sleep disruption and functional impairment in affected individuals. Whether SARS-CoV-2 infection directly increases the incidence of RLS, exacerbates pre-existing susceptibility, or produces symptoms that mimic RLS remains incompletely established.<\/p>\n\n\n\n Objective:<\/strong> To review the epidemiological evidence, physiological mechanisms, genomic susceptibility, pathological substrates, clinical diagnostic procedures, and therapeutic approaches relevant to RLS occurring in the context of long COVID.<\/p>\n\n\n\n Methods:<\/strong> This narrative review synthesizes observational research on RLS and long COVID, established RLS diagnostic criteria, literature on iron-dependent neural physiology and genetic susceptibility, and contemporary clinical practice guidelines for treatment.<\/p>\n\n\n\n Results:<\/strong> A small observational study reported an increase in RLS prevalence among women with long COVID compared with their recalled pre-COVID status, providing preliminary evidence of a possible association. However, the available evidence does not establish causality or quantify risk reliably across the broader population. Established RLS biology implicates central nervous system iron regulation, dopaminergic signaling, circadian modulation, and genetic susceptibility. Post-COVID inflammatory and immune dysregulation, altered sleep\u2013wake regulation, medication exposure, and exacerbation of iron deficiency or systemic disease are plausible contributors, but remain insufficiently tested as RLS-specific mechanisms. Diagnosis is clinical and requires exclusion of mimicking conditions. Evaluation should include iron studies, assessment of exacerbating medications and untreated sleep apnea, and targeted investigation of renal, neurological, and metabolic contributors. Evidence-based treatment includes correction of appropriate iron deficiency, gabapentinoid therapy when indicated, management of exacerbating factors, and selected specialist-directed interventions.<\/p>\n\n\n\n Conclusions:<\/strong> RLS is a clinically important but under-investigated potential component of long COVID. Future studies should establish incidence prospectively, distinguish true RLS from neuropathic and other leg symptoms, and test whether post-infectious biological mechanisms identify a distinct treatment-responsive subgroup.<\/p>\n\n\n\n Long COVID encompasses a range of symptoms persisting or emerging after acute SARS-CoV-2 infection. Neurological and sleep-related manifestations include fatigue, cognitive dysfunction, altered sensory perception, autonomic symptoms, insomnia, and disrupted sleep architecture. Their coexistence may produce substantial morbidity even when routine neurological examination or conventional laboratory testing fails to identify a unifying abnormality.[1,2]<\/p>\n\n\n\n Restless legs syndrome (RLS), also known as Willis\u2013Ekbom disease, is a sensorimotor neurological disorder characterized by an urge to move the legs, typically accompanied by unpleasant sensations that arise or worsen during rest, improve with movement, and exhibit an evening or nighttime predominance. Clinically significant RLS can impair sleep initiation, fragment sleep, worsen daytime fatigue, and diminish quality of life.[3]<\/p>\n\n\n\n The relationship between RLS and long COVID is biologically plausible but not yet well characterized. Weinstock and colleagues reported that RLS prevalence among women with long COVID increased from 5.7% before COVID-19 to 14.8% afterward, compared with 6.7% among female controls.[4] The study raised the possibility of a post-infectious association but relied on a selected population and recalled pre-infection symptoms. Its findings therefore cannot establish that SARS-CoV-2 directly causes RLS, nor can they be generalized without qualification to men, all age groups, or the wider population.<\/p>\n\n\n\n A further diagnostic challenge is that long COVID can produce leg discomfort through peripheral neuropathy, muscle pain, cramps, akathisia, vascular disease, edema, and medication effects. These conditions may coexist with genuine RLS, but they are not interchangeable diagnoses. The defining relationship between symptoms, rest, movement, and circadian timing is central to distinguishing RLS from these alternatives.<\/p>\n\n\n\n This review examines the current evidence and proposes a clinically grounded framework for investigating and treating RLS in people with long COVID.<\/p>\n\n\n\n The association between RLS and long COVID remains supported primarily by limited observational evidence rather than large prospective cohorts. The study by Weinstock et al. provides an initial signal that RLS symptoms may become more prevalent after COVID-19 in at least some patients.[4] However, several limitations affect interpretation: selection of patients with long COVID, reliance on retrospective reporting of pre-infection symptoms, potential confounding by sleep disorders and medication use, and limited evidence of generalizability across demographic groups.<\/p>\n\n\n\n The available data do not determine whether post-COVID RLS represents newly incident disease, worsening of previously mild RLS, increased awareness of symptoms during prolonged illness, or misclassification of other leg symptoms. Nor do they establish whether RLS is more frequent following SARS-CoV-2 infection than after other systemic infections.<\/p>\n\n\n\n These distinctions have practical consequences. A patient who reports severe nocturnal leg discomfort after COVID-19 may have newly developed RLS, pre-existing RLS aggravated by illness, iron-deficiency-associated symptoms, peripheral neuropathy, or multiple coexisting disorders. Correct classification is necessary before the symptoms can be attributed to a particular mechanism or used to justify treatment.<\/p>\n\n\n\n Prospective studies should assess RLS before infection where possible, document onset and severity afterward, and use standardized diagnostic criteria. Appropriate comparison groups include infected individuals who recover without long COVID, patients with long COVID without RLS, and patients with comparable post-infectious symptoms following other infections.<\/p>\n\n\n\n Iron biology is among the most consistently supported components of RLS pathophysiology. Iron participates in neuronal metabolism, mitochondrial function, myelination, and neurotransmitter synthesis. Iron availability also influences tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis.<\/p>\n\n\n\n Studies of RLS have identified evidence consistent with altered central nervous system iron regulation, including findings from cerebrospinal fluid, neuroimaging, and neuropathological investigations.[5,6] These observations support a model in which brain iron availability or handling is abnormal in at least a proportion of affected individuals.<\/p>\n\n\n\n Importantly, serum ferritin and brain iron stores are not equivalent measurements. Peripheral iron indices are clinically useful for identifying patients likely to benefit from iron replacement, but normal circulating iron measures do not necessarily establish normal iron physiology within the central nervous system.<\/p>\n\n\n\n Iron deficiency may also occur without overt anemia. Consequently, a normal hemoglobin concentration does not exclude clinically relevant iron depletion in a patient with RLS.<\/p>\n\n\n\n Dopaminergic pathways participate in motor control, sensory processing, and the regulation of movement across the sleep\u2013wake cycle. RLS is associated with altered dopaminergic function, although its pathophysiology cannot be reduced to a simple deficiency of dopamine.<\/p>\n\n\n\n Dopaminergic drugs can relieve symptoms, but long-term treatment with dopamine agonists may cause augmentation: a treatment-associated worsening in which symptoms begin earlier in the day, develop more rapidly during rest, become more intense, or spread to additional body regions. This phenomenon has important implications for long-term prescribing.<\/p>\n\n\n\n Current treatment guidelines increasingly favor alpha-2-delta ligands, including gabapentin and pregabalin, for many adults requiring pharmacological therapy, while discouraging routine standard use of dopamine agonists because of augmentation and other adverse effects.[7]<\/p>\n\n\n\n RLS exhibits a characteristic evening and nighttime predominance. Circadian regulation affects neural excitability, body temperature, hormone secretion, sleep propensity, and dopamine-related signaling. The clinical expression of RLS likely reflects interactions between circadian processes, iron-dependent physiology, and sensorimotor neural circuits.<\/p>\n\n\n\n Long COVID commonly involves sleep disturbance and altered daily activity patterns. These changes may amplify the burden of pre-existing RLS or complicate recognition of newly emerging disease. Nevertheless, circadian disruption in long COVID has not been demonstrated to be a specific causal mechanism for RLS.<\/p>\n\n\n\n RLS is understood as a neurological disorder involving central sensorimotor networks rather than a primary disorder of the leg muscles. Spinal excitability and descending neural modulation may contribute to the sensory urge and repetitive movements associated with the condition. Periodic limb movements during sleep frequently accompany RLS, but they are neither necessary nor sufficient for the diagnosis.<\/p>\n\n\n\n This distinction is important when evaluating patients with long COVID, in whom muscle discomfort, peripheral nerve symptoms, and involuntary movements may occur through several mechanisms.<\/p>\n\n\n\n SARS-CoV-2 infection can produce substantial innate and adaptive immune activation. In some individuals, immune signaling remains altered after the acute infection. Persistent inflammatory activity, altered cytokine signaling, and changes in neuroimmune communication have been proposed as contributors to long-COVID manifestations.[1,2]<\/p>\n\n\n\n The hypothesis that post-infectious immune dysregulation contributes to RLS is plausible, particularly in patients whose symptoms begin after infection and coexist with other post-infectious neurological or autonomic manifestations. The observational association reported by Weinstock et al. also raises this possibility.[4]<\/p>\n\n\n\n However, no established biomarker currently identifies an immune-mediated subtype of post-COVID RLS. The available evidence does not demonstrate that a particular cytokine, autoantibody, or inflammatory pathway causes the syndrome in this population. A post-infectious immune mechanism should therefore be treated as a research hypothesis rather than a proven explanation for an individual patient’s symptoms.<\/p>\n\n\n\n Acute and chronic illness may alter nutritional intake, iron metabolism, inflammation, gastrointestinal function, and the interpretation of iron indices. Long COVID may also coexist with anemia, chronic kidney disease, blood loss, or other disorders affecting iron availability.<\/p>\n\n\n\n These factors could worsen RLS in susceptible individuals without requiring a unique SARS-CoV-2-specific mechanism. Inflammation can elevate ferritin, making ferritin alone difficult to interpret in some clinical circumstances; transferrin saturation provides complementary information.<\/p>\n\n\n\n A rigorous evaluation should distinguish iron deficiency as a potentially treatable contributor from the broader hypothesis that COVID-19 directly alters central nervous system iron homeostasis.<\/p>\n\n\n\n Dysautonomia, orthostatic intolerance, and sleep disturbance are reported in long COVID. These symptoms can coexist with RLS and magnify its consequences. Repeated awakenings, inadequate restorative sleep, and fatigue may reduce functional reserve and intensify perceived symptom burden.<\/p>\n\n\n\n Nevertheless, autonomic dysfunction is not a diagnostic criterion for RLS, and its presence does not establish a shared pathological mechanism. Studies should assess RLS, periodic limb movements, sleep apnea, insomnia, and autonomic abnormalities separately before investigating their interactions.<\/p>\n\n\n\n Patients with long COVID may receive medications that affect sleep, alertness, or motor restlessness. Antihistaminergic, serotonergic, and antidopaminergic medications can exacerbate RLS in some individuals. Sedating medicines may also worsen daytime impairment even when they improve sleep initiation.<\/p>\n\n\n\n Medication exposure should therefore be reviewed systematically. A temporal relationship between starting or increasing a medication and worsening leg symptoms may be clinically informative, although medication changes should be made with the prescribing clinician rather than abruptly or without supervision.<\/p>\n\n\n\n Peripheral neuropathy can produce burning, tingling, numbness, electric-shock sensations, and pain in the legs. Such symptoms may occur at rest and disrupt sleep, but they do not necessarily exhibit the characteristic circadian pattern or sustained relief with movement required for RLS.<\/p>\n\n\n\n RLS and neuropathy can coexist. In these cases, patients may describe both persistent sensory abnormalities and a separate urge to move that becomes prominent during inactivity in the evening. The distinction matters because treatment directed at neuropathic pain may not adequately control RLS, and treatment for RLS will not necessarily correct structural nerve injury.<\/p>\n\n\n\n RLS has a substantial genetic component, especially in familial and earlier-onset disease. Genome-wide association studies have identified susceptibility loci involving MEIS1<\/em>, BTBD9<\/em>, and the MAP2K5\/LBXCOR1<\/em> region, among other loci.[8] These findings implicate developmental, neuronal, and sensorimotor pathways, although the precise functional effects of many associated variants remain under investigation.<\/p>\n\n\n\n Genetic susceptibility is not deterministic. Variants alter probability rather than establish diagnosis, and environmental factors, iron status, age, pregnancy, renal disease, and medication exposure can influence clinical expression.<\/p>\n\n\n\n At present, there is insufficient evidence that specific genetic variants predispose individuals to RLS specifically after SARS-CoV-2 infection. General RLS susceptibility genes provide a rational starting point for research, but they cannot be treated as validated long-COVID risk markers.<\/p>\n\n\n\n Potential interactions among host genetics, immune regulation, iron homeostasis, and circadian pathways deserve investigation. For example, a person with an inherited predisposition to RLS might develop more prominent symptoms after systemic illness, nutritional disturbance, or changes in medication exposure. This is a plausible gene\u2013environment model, not an established mechanism of post-COVID disease.<\/p>\n\n\n\n Prospective studies should compare patients with post-COVID RLS against infected individuals without RLS, patients with long COVID without RLS, and patients with RLS unrelated to COVID-19. All groups should undergo standardized clinical phenotyping and assessment of iron status, renal function, medications, sleep disorders, and relevant comorbidities.<\/p>\n\n\n\n Genetic analyses should examine established RLS susceptibility loci while also exploring immune-regulatory and circadian pathways. Findings would require replication across independent cohorts and diverse ancestral populations. Functional studies would then be necessary to determine whether associated variants alter relevant biological processes.<\/p>\n\n\n\n No genetic test currently has established clinical utility for predicting post-COVID RLS or selecting its treatment.<\/p>\n\n\n\n Unlike some peripheral neuropathies, RLS does not have a single validated tissue biopsy, imaging study, blood test, or electrophysiological result that confirms the diagnosis. It remains primarily a clinical diagnosis based on the characteristic symptom pattern and exclusion of mimicking conditions.[3,9]<\/p>\n\n\n\n Research into RLS pathology has implicated central nervous system iron regulation, dopamine-related pathways, and sensorimotor network function. However, these observations do not provide a specific pathological signature for RLS following COVID-19.<\/p>\n\n\n\n Routine nerve-conduction studies and electromyography do not diagnose RLS. They may be appropriate when examination suggests peripheral neuropathy, radiculopathy, motor neuron disease, or another neuromuscular condition. Polysomnography can identify periodic limb movements during sleep and evaluate coexisting sleep disorders, but it is not required for an otherwise clear clinical diagnosis of RLS.<\/p>\n\n\n\n Future studies should examine whether patients with post-COVID RLS exhibit distinctive changes in iron indices, sleep architecture, inflammatory markers, autonomic function, or neuroimaging. Such measures must be evaluated against appropriate controls before they can be considered biomarkers of a post-COVID-specific mechanism.<\/p>\n\n\n\n The International Restless Legs Syndrome Study Group (IRLSSG) established five essential diagnostic criteria.[3] All must be satisfied for a clinical diagnosis:<\/p>\n\n\n\n The fifth criterion is especially important in long COVID because neuropathic pain, musculoskeletal symptoms, and medication-related restlessness may closely resemble RLS.<\/p>\n\n\n\n The history should establish symptom timing, frequency, severity, sleep consequences, response to movement, and whether symptoms existed before COVID-19. The clinician should also ask about symptom spread to the arms, family history, previous RLS treatment, and possible medication-associated augmentation.<\/p>\n\n\n\n Important mimics include peripheral neuropathy, nocturnal leg cramps, radiculopathy, musculoskeletal pain, venous stasis, positional discomfort, akathisia, and medication-induced restlessness. Periodic limb movements during sleep are related to RLS but do not independently establish the diagnosis.<\/p>\n\n\n\n In patients with long COVID, the differential should also include coexisting obstructive sleep apnea, renal disease, iron deficiency, anemia, thyroid disorders, and other causes of sleep fragmentation or leg discomfort.<\/p>\n\n\n\n A careful examination can identify edema, focal neurological deficits, reduced reflexes, sensory loss, muscle wasting, vascular abnormalities, or musculoskeletal disease. These findings may indicate an alternative diagnosis or a condition coexisting with RLS.<\/p>\n\n\n\n The American Academy of Sleep Medicine (AASM) recommends regular iron studies for clinically significant RLS, including serum ferritin and transferrin saturation.[7] Testing is ideally performed in the morning, avoiding iron-containing supplements and foods for at least 24 hours beforehand when feasible and consistent with laboratory instructions.<\/p>\n\n\n\n The AASM guideline states that adults with ferritin at or below 75 ng\/mL or transferrin saturation below 20% may be candidates for oral or intravenous iron, depending on the circumstances. When ferritin is between 75 and 100 ng\/mL, the consensus approach favors intravenous iron if iron treatment is indicated. These thresholds are specific to RLS management and differ from conventional criteria for defining iron deficiency in the general population.<\/p>\n\n\n\n Additional testing should be directed by the clinical context and may include complete blood count, renal function, glucose or glycated hemoglobin, thyroid function, vitamin B12, and selected investigations for blood loss or other causes of iron deficiency.<\/p>\n\n\n\n Patients should be assessed for insomnia, obstructive sleep apnea, insufficient sleep, circadian disturbance, and periodic limb movements when clinically indicated. Polysomnography is particularly useful when another sleep disorder is suspected or when the diagnosis remains uncertain.<\/p>\n\n\n\n Sleep apnea deserves special attention because untreated disease can worsen sleep quality and daytime impairment, and it is identified in current treatment guidance as a factor to address before escalating RLS medication.[7]<\/p>\n\n\n\n The International RLS Study Group Rating Scale can quantify symptom severity and help monitor response. Baseline assessment should also document sleep duration, sleep initiation, awakenings, daytime fatigue, mobility, and functional limitations.<\/p>\n\n\n\n For research purposes, the distinction between newly incident RLS, worsening of pre-existing RLS, and symptoms ultimately attributable to another condition should be recorded explicitly. This would improve the reliability of future epidemiological estimates.<\/p>\n\n\n\n The first management step is to identify and address reversible factors. These include iron deficiency, untreated obstructive sleep apnea, excessive caffeine or alcohol, and potentially exacerbating medications. Medication review should consider antihistaminergic, serotonergic, and antidopaminergic agents.[7]<\/p>\n\n\n\n Patients should not discontinue prescribed antidepressants, antipsychotics, antihistamines, or other medicines without consulting their clinician. Where a drug appears to exacerbate RLS, alternatives and the risks of changing therapy should be assessed individually.<\/p>\n\n\n\n Iron replacement is appropriate when iron indices and clinical circumstances support treatment. Oral ferrous sulfate may be effective in selected patients, although gastrointestinal adverse effects and reduced absorption can limit tolerability. Intravenous ferric carboxymaltose has a strong AASM recommendation for adults with appropriate iron status; other intravenous formulations have conditional recommendations.[7]<\/p>\n\n\n\n The choice of preparation and route should consider iron indices, inflammation, gastrointestinal tolerance, kidney function, previous response, and the likelihood of ongoing iron loss. Intravenous iron is not appropriate simply because a patient has long COVID or RLS; eligibility and safety require clinical assessment. Ferric carboxymaltose can cause hypophosphatemia, and intravenous iron carries additional formulation-specific risks.<\/p>\n\n\n\n Gabapentin, pregabalin, and gabapentin enacarbil are recommended options for adults with clinically significant RLS. These medicines can improve symptoms, sleep quality, and quality of life.[7]<\/p>\n\n\n\n Their effects should be balanced against somnolence, dizziness, edema, and impaired balance. Renal dose adjustment is important in chronic kidney disease. In older adults, and in patients taking opioids or other sedating medicines, careful dosing and monitoring are particularly important because of the risk of falls, excessive sedation, and respiratory depression.<\/p>\n\n\n\n For patients with long COVID who already experience fatigue, cognitive impairment, or unsteadiness, treatment should begin conservatively and be assessed for net functional benefit rather than symptom relief alone.<\/p>\n\n\n\n Pramipexole, ropinirole, and rotigotine can reduce RLS symptoms, but current AASM guidance recommends against their standard routine use because long-term treatment can produce augmentation.[7] This treatment-related worsening may eventually make symptoms more severe and difficult to manage.<\/p>\n\n\n\n Dopamine agonists may still be considered in selected circumstances after discussion of risks, benefits, and alternatives. Patients already taking them should not stop abruptly without medical guidance; a supervised transition may be necessary.<\/p>\n\n\n\n For selected patients with persistent, severe RLS despite correction of contributing factors and appropriate first-line treatment, specialist-directed options may include additional pharmacological strategies. The AASM conditionally supports certain opioid treatments for appropriately selected adults with refractory RLS, but these medicines carry risks of respiratory depression, dependence, sedation, and interactions with other central nervous system depressants.<\/p>\n\n\n\n Opioids require particular caution in patients with sleep apnea, chronic respiratory disease, renal impairment, or concurrent sedative use. Their use should not be inferred to be appropriate merely because RLS occurs in long COVID.<\/p>\n\n\n\n Bilateral high-frequency peroneal nerve stimulation is another option supported by a conditional AASM recommendation for selected adults. Availability, suitability, cost, and the quality of evidence should be discussed with a specialist.<\/p>\n\n\n\n Regular sleep schedules, moderate activity within the individual’s tolerance, stretching, walking during symptomatic periods, and reduction of aggravating substances may help some patients. These measures are adjuncts rather than substitutes for iron evaluation and appropriate treatment of clinically significant disease.<\/p>\n\n\n\n Because post-exertional symptom exacerbation can occur in long COVID, activity recommendations should be individualized. Fixed exercise escalation may be inappropriate for patients whose symptoms worsen substantially after exertion. Energy management and pacing may be more suitable.<\/p>\n\n\n\n Cognitive behavioral approaches may help address coexisting insomnia, although they do not directly establish or reverse the underlying RLS mechanism. Evidence for several complementary approaches remains insufficient to recommend them as specific RLS treatments.<\/p>\n\n\n\n Several questions remain unresolved.<\/p>\n\n\n\n First, large prospective cohorts are needed to determine whether SARS-CoV-2 infection increases the incidence of RLS, exacerbates pre-existing disease, or simply increases recognition of symptoms. Standardized pre-infection and post-infection assessment would reduce recall bias.<\/p>\n\n\n\n Second, studies should establish whether post-COVID RLS has a distinct clinical phenotype. This requires careful differentiation from peripheral neuropathy, cramps, akathisia, and other sleep disorders.<\/p>\n\n\n\n Third, mechanistic research should evaluate iron homeostasis, inflammatory signaling, circadian regulation, autonomic function, and relevant genetic variants in appropriately matched groups. The objective should be to identify reproducible mechanisms rather than assume that all RLS occurring after COVID-19 is immune-mediated.<\/p>\n\n\n\n Fourth, treatment trials should determine whether people with post-COVID RLS respond differently from patients with conventional RLS. Outcomes should include symptom severity, sleep quality, daytime function, treatment adverse effects, and durability of benefit.<\/p>\n\n\n\n Finally, studies should stratify results by sex, age, kidney function, iron status, medication exposure, and coexisting sleep disorders. Such variables may be more immediately useful for clinical care than an undifferentiated long-COVID label.<\/p>\n\n\n\n Restless legs syndrome may be an under-recognized contributor to sleep disturbance and neurological morbidity in some individuals with long COVID. Preliminary observational evidence suggests a possible association, but current research does not establish a causal relationship or a distinct post-COVID RLS mechanism.<\/p>\n\n\n\n Established RLS physiology implicates central nervous system iron regulation, dopaminergic signaling, circadian processes, and genetic susceptibility. Post-infectious immune dysregulation and altered sleep\u2013wake regulation are plausible hypotheses, but their specific roles in RLS following COVID-19 remain unproven.<\/p>\n\n\n\n Clinical evaluation should rely on established diagnostic criteria, systematic exclusion of mimicking conditions, iron studies, medication review, and assessment of coexisting sleep disorders. Appropriate iron replacement, alpha-2-delta ligand therapy, correction of exacerbating factors, and selected specialist-directed interventions can provide meaningful symptom relief.<\/p>\n\n\n\n The immediate priority is not to assume a unique post-COVID disease mechanism, but to improve diagnostic precision and treatment of a potentially disabling condition. Prospective epidemiology and mechanistic studies are required to determine whether a biologically distinct, treatment-responsive post-COVID RLS subgroup exists.<\/p>\n\n\n\n1. Introduction<\/h5>\n\n\n\n
2. Epidemiological Evidence and Clinical Significance<\/h5>\n\n\n\n
3. Physiology and Established Pathophysiology of RLS<\/h5>\n\n\n\n
3.1 Central nervous system iron homeostasis<\/h5>\n\n\n\n
3.2 Dopaminergic signaling and sensorimotor regulation<\/h5>\n\n\n\n
3.3 Circadian regulation<\/h5>\n\n\n\n
3.4 Spinal and sensorimotor pathways<\/h5>\n\n\n\n
4. Candidate Mechanisms Linking Long COVID and RLS<\/h5>\n\n\n\n
4.1 Post-infectious immune dysregulation<\/h5>\n\n\n\n
4.2 Iron deficiency and systemic illness<\/h5>\n\n\n\n
4.3 Autonomic dysfunction and altered sleep regulation<\/h5>\n\n\n\n
4.4 Medication effects and symptom amplification<\/h5>\n\n\n\n
4.5 Distinguishing RLS from post-COVID peripheral neuropathy<\/h5>\n\n\n\n
5. Genomic Susceptibility<\/h5>\n\n\n\n
5.1 Established genetic contributions to RLS<\/h5>\n\n\n\n
5.2 Is there a genetic basis for post-COVID RLS?<\/h5>\n\n\n\n
5.3 Priorities for genomic research<\/h5>\n\n\n\n
6. Pathology and Objective Biomarkers<\/h5>\n\n\n\n
7. Clinical Diagnosis and Evaluation<\/h5>\n\n\n\n
7.1 The five essential clinical criteria<\/h5>\n\n\n\n
\n
7.2 Differential diagnosis<\/h5>\n\n\n\n
7.3 Laboratory evaluation and iron studies<\/h5>\n\n\n\n
7.4 Sleep assessment<\/h5>\n\n\n\n
7.5 Severity and longitudinal assessment<\/h5>\n\n\n\n
8. Treatment and Symptom Relief<\/h5>\n\n\n\n
8.1 Correct exacerbating factors<\/h5>\n\n\n\n
8.2 Iron replacement<\/h5>\n\n\n\n
8.3 Alpha-2-delta ligands<\/h5>\n\n\n\n
8.4 Dopamine agonists and augmentation<\/h5>\n\n\n\n
8.5 Other treatments and severe refractory RLS<\/h5>\n\n\n\n
8.6 Behavioral and nonpharmacological measures<\/h5>\n\n\n\n
9. Research Priorities<\/h5>\n\n\n\n
10. Conclusions<\/h5>\n\n\n\n
Footnotes<\/h5>\n\n\n\n
\n
References<\/h5>\n\n\n\n